Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The BUY prediction by Finanzgonzo finished with a performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 12.955% | 12.955% | 67.022% | 9.033% |
| iShares Core DAX® | -1,36 % | -2,16 % | 2,08 % | 52,68 % |
| iShares Nasdaq 100 | -3,70 % | -1,16 % | 32,60 % | 88,75 % |
| iShares Nikkei 225® | -2,51 % | 7,93 % | 58,27 % | 82,31 % |
| iShares S&P 500 | -1,66 % | -0,70 % | 22,96 % | 66,08 % |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)